A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

Summary: The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patient...

Full description

Bibliographic Details
Main Authors: Andrew Kosmopoulos, Deepak L. Bhatt, Gus Meglis, Raj Verma, Yi Pan, Adrian Quan, Hwee Teoh, Maya Verma, Lixia Jiao, Robert Wang, Rebecca A. Juliano, Mahesh Kajil, Mikhail N. Kosiborod, Basel Bari, Abdullahi A. Berih, Mallory Aguilar, Antonnette Escano, Andrew Leung, Idelta Coelho, Makoto Hibino, Rafael Díaz, R. Preston Mason, Ph. Gabriel Steg, Tabassome Simon, Alan S. Go, Andrew P. Ambrosy, Richard Choi, Arthur M. Kushner, Lawrence A. Leiter, Mohammed Al-Omran, Subodh Verma, C. David Mazer
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:iScience
Subjects:
Health sciences
Medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221010087

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221010087

Similar Items